Ceredex Value Advisors’s Patterson-UTI PTEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.94M Buy
+543,500
New +$5.97M 0.19% 159
2025
Q2
– Sell
-1,363,150
Closed -$11.2M – 189
2025
Q1
$11.2M Buy
1,363,150
+32,800
+2% +$275K 0.25% 133
2024
Q4
$11M Buy
1,330,350
+84,950
+7% +$681K 0.22% 132
2024
Q3
$9.5M Buy
1,245,400
+84,200
+7% +$776K 0.19% 140
2024
Q2
$12M Buy
+1,161,200
New +$12.7M 0.23% 115
2023
Q2
– Sell
-972,800
Closed -$11.4M – 180
2023
Q1
$11.4M Buy
+972,800
New +$14.2M 0.18% 134
2018
Q4
– Sell
-2,432,500
Closed -$41.6M – 180
2018
Q3
$41.6M Buy
2,432,500
+362,550
+18% +$6.23M 0.47% 84
2018
Q2
$37.3M Buy
2,069,950
+33,300
+2% +$668K 0.43% 103
2018
Q1
$35.7M Buy
+2,036,650
New +$42.5M 0.42% 111

Other funds holding PTEN

Ceredex Value Advisors's PTEN Position: Q3 2026 in Review

Ceredex Value Advisors opened a new position in Patterson-UTI (PTEN) in Q3 2026: 543,500 shares worth $5.94M. The stake represents 0.19% of the portfolio and ranks #159 among its holdings. This is a return to the name: Ceredex Value Advisors previously reported a position in PTEN as recently as Q1 2025.

Ceredex Value Advisors first reported a position in PTEN in Q1 2018 and has held it in 9 quarters since. The position peaked at $41.6M in Q3 2018. 241 funds tracked by Wall St. Rank hold PTEN as of Q3 2026.

  • Ceredex Value Advisors held 543,500 shares of Patterson-UTI worth $5.94M as of Q3 2026.
  • Patterson-UTI was a new Ceredex Value Advisors position in Q3 2026.
  • Patterson-UTI made up 0.19% of Ceredex Value Advisors's portfolio in Q3 2026, its #159 holding.
  • Ceredex Value Advisors first reported a position in Patterson-UTI in Q1 2018 and has held it in 9 quarters since.
  • Ceredex Value Advisors's Patterson-UTI position peaked at $41.6M in Q3 2018.
  • 241 funds tracked by Wall St. Rank held Patterson-UTI as of Q3 2026.

Based on Ceredex Value Advisors's 13F filing for Q3 2026, filed 9 Nov 2026.